Predictive factors for response to chemotherapy in colorectal cancer patients

Critical Reviews in Oncology/Hematology

Volumn 52, Issue 1, 2004, Pages 45-60

  Vincenzi, Bruno ^a   Cesa, Annalisa La ^a   Santini, Daniele ^a   Schiavon, Gaia ^a   Grilli, Claudia ^a   Graziano, Francesco ^b   Tonini, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b Medical Oncology Unit   (Italy)

Author keywords

Chemotherapy; Colorectal cancer; Predictive factors

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CELECOXIB; CETUXIMAB; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; MICROSATELLITE DNA; OXALIPLATIN; PEMETREXED; RALTITREXED; ROFECOXIB; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DNA METHYLATION; DRUG RESPONSE; DRUG TARGETING; HUMAN; MICROSATELLITE INSTABILITY; MOLECULAR DYNAMICS; NEUTROPENIA; PREDICTION; PROTEIN TARGETING; PROTO ONCOGENE; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; COLORECTAL NEOPLASMS; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 4444250665     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2004.05.005     Document Type: Review

References (139)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., et al. Cancer statistics 2001. CA Cancer J. Clin. 51:2001;15-36
2. Bleiberg H. Colorectal cancer - is there an alternative to 5-FU? Eur. J. Cancer. 33:1997;536-541
3. Machover D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer. 80:1997;1179-1187
4. Rustum Y.M., Harstrick A., Cao S., et al. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J. Clin. Oncol. 15:1997;389-400
5. Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-8.
6. Popescu R.A., Norman A., Ross P.J., Parikh B., Cunningham D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J. Clin. Oncol. 17:1999;2412-2428
7. Taal B.G., Van Tinteren H., Zoetmulder F.A. Adjuvant 5-FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br. J. Cancer. 85:2001;1437-1443
8. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999;1356.
9. Buroker T.R., O'Connell M.J., Wieand H.S., et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J. Clin. Oncol. 12:1994;14-20
10. Aschele C., Sobrero A., Faderan M.A., Bertino J.M. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res. 52:1992;1855-1864
11. Sobrero A.F., Aschele C., Bertino J.R. Fluorouracil in colorectal cancer - a tale of two drugs: implications for biochemical modulation. J. Clin. Oncol. 15:1997;368-381
12. Lokich J.L., Ahlgren J.D., Gullo J.L., Phillips J.A., Fryer J.G. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J. Clin. Oncol. 7:1989;425-432
13. Sotos G.A., Grogan L., Allegra C.J. Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treat. Rev. 20:1994;11-49
14. Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trails testing the biochemical modulation of fluorouracil by methotrexate. J Clin Oncol 1994;12:960-9.
15. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 343:2000;905-914
16. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 355:2000;1041-1047
17. Levi F., Zidani R., Misset J.L. Randomized multicentre trial of oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 350:1997;681-686
18. Sargent D.J., Niedwiecki D., O'Connell M.J., Schilsky R.L. Recommendation for caution with irinotecan fluorouracil and leucovorin for colorectal cancer. N. Eng. J. Med. 345:2001;690-692
19. Vanhoefer U., Harstrick A., Achterrath W., Cao S., Seeber S., Rustum Y.M. Irinotecan in the treatment of colorectal cancer: clinical overview. J. Clin. Oncol. 19:2001;1501-1518
20. Welt S., Ritter G., Williams C., et al. Preliminary report of a phase I study of combination chemotherapy and humanized a33 antibody immunotherapy in patients with advanced colorectal cancer. Clin. Cancer Res. 9:2003;1347-1353
21. Fishman A.D., Wadler S. Advances in the treatment of metastatic colorectal cancer. Clin. Colorectal Cancer. 1:2001;20-35
22. Hasan J., Jayson G.C. VEGF antagonists. Expert Opin. Biol. Ther. 1:2001;703-718
23. Beretta G.D., Pessi M.A., Poletti P., Mosconi S., Labianca R. New drugs and combinations in the palliative treatment of colon and rectal cancer. Eur. J. Surg. Oncol. 27:2001;595-600
24. Grothey A., Schmoll H.J. New chemotherapy approaches in colorectal cancer. Curr. Opin. Oncol. 13:2001;275-286
25. Haller D.G. Update on chemotherapy for advanced colorectal cancer. Oncology (Huntingt). 15:2001;11-15
26. Sharma R.A., Manson M.M., Gescher A., Steward W.P. Colorectal cancer chemoprevention: biochemical targets and clinical development of promising agents. Eur. J. Cancer. 37:2001;12-22
27. Chau I., Cunningham D. Chemotherapy in colorectal cancer: new options and new challenges. Br. Med. Bull. 64:2002;159-180
28. Chau I., Cunningham D. Cyclooxygenase inhibition in cancer - a blind alley or a new therapeutic reality? N. Engl. J. Med. 346:2002;1085-1087
29. Watanabe T., Wu T.T., Catalano P.J., et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 344:2001;1196-1206
30. Imperiale T.F. Aspirin and the prevention of colorectal cancer. N. Engl. J. Med. 348:2003;879-880
31. Iqbal S., Lenz H.J. Determinants of prognosis and response to therapy in colorectal cancer. Curr. Oncol. Rep. 3:2001;102-108
32. Johnson M.R., Diasio R.B. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv. Enzyme Regul. 41:2001;151-157
33. Grem JL. 5-Fluoropyrimidines. In: Chabner BA, Long DL, editors. Cancer Chemotherapy and Biotherapy, 2nd ed. Philadelphia: Lippincott-Raven Publishers, 1996. p. 149-212.
34. Milano G, Etienne MC. Fluorinated pyrimidines. In: Grochow LB, Ames MM, editors. A Clinician's Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics. Baltimore: Williams and Wilkins, 1998. p. 289-300.
35. Leichman C.G., Lenz H.J., Leichman L., et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol. 10:1997;3223-3229
36. Lenz H.J., Danenberg K.D., Leichman C.G., et al. p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin. Cancer Res. 5:1998;1227-1234
37. Aschele C., Lonardi S., Monfardini S. Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat. Rev. 28:2002;27-47
38. Edler D., Glimelius B., Hallstrom M., et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J. Clin. Oncol. 20(7):2002;1721-1728
39. Johnston P.G., Fisher E.R., Rockette H.E., et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J. Clin. Oncol. 12:1994;2640-2647
40. Yamachika T., Nakanishi H., Inada K., et al. A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer. 82:1998;70-77
41. Takenoue T., Hirokazu N., Matsuda K., et al. Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann. Surg. Oncol. 7:2000;193-198
42. Banerjee D., Gorlick R., Liefshitz A., et al. Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase. Cancer Res. 60:2000;2365-2367
43. Johnston P.G., Benson A.l.B. III, Catalano P., et al. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J. Clin. Oncol. 21(5):2003;815-819
44. Etienne M.C., Chazal M., Laurent-Puig P., et al. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J. Clin. Oncol. 20(12):2002;2832-2843
45. Aschele C., Debernardis D., Tunesi G., Maley F., Sobrero A. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin. Cancer Res. 6(12):2000;4797-4802
46. Cascinu S., Aschele C., Barni S., et al. Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin. Cancer Res. 5(8):1999;1996-1999
47. Kornmann M., Link K.H., Lenz H.J., et al. Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer Lett. 118(1):1997;29-35
48. Kitchens M.E., Forsthoefel A.M., Rafique Z., Spencer H.T., Berger F.G. Ligand-mediated induction of thymidylate synthase occurs by enzyme stabilization. Implications for autoregulation of translation. J. Biol. Chem. 274:1999;12544-12547
49. Grem J.L., Danenberg K.D., Behan K., et al. Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen. Clin. Cancer Res. 7:2001;999-1009
50. Pullarkat V, Ghaderi SA, Ingle YP. Human thymidylate synthase gene polymorphism determines response to 5-FU. Proc Am Soc Clin Oncol 2000 [abstr 942].
51. Iacopetta B., Grieu F., Joseph D., Elsaleh H. A polymorphism in the enhancer region of thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br. J. Cancer. 85(6):2001;827-830
52. Pullarkat St., Stoehlmacher J., Ghaderi V., et al. Thymidilate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogen. J. 1(1):2001;65-70
53. Danenberg K., Danenberg K.D., Uchida P.V., et al. Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin. Cancer Res. 10:2004;433-439
54. Marsh S., McLeod H.L. Thymidylate synthase pharmacogenetics in colorectal cancer. Clin. Colorectal Cancer. 1(3):2001;175-178. discussion 179-181
55. Martinez-Balibrea E., Abad A., Manzano J.L., et al. Predictive value of thymidylate synthase. Proc. Am. Soc. Clin. Oncol. 22:2003;268. [abstr 1075]
56. Kawakami K., Watanabe G. Single nucleotide polymorphism in the tandem-repeat sequence of thymidylate synthase gene: a candidate for an additional predictor in 5-FU-based chemotherapy. Proc. Am. Soc. Clin Oncol. 22:2003;127. [abstr 509]
57. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 12:1998;2245-2262
58. Muller H., Helin K. The E2F transcription factors: key regulators of cell proliferation. Biochim. Biophys. Acta. 1470:2000;1-12
59. Banerjee D., Mayer-Kuckuk P., Capiaux G., Budak-Alpdogan T., Gorlick R., Bertino J.R. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim. Biophys. Acta. 1587:2002;164-173
60. Etienne M.C., Ilc K., Formento J.L., et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity. Br. J. Cancer. 90:2004;526-534
61. Moghaddam Mh., Bicknell R. Expression of plateled-derived endothelial cell grow factor in Escherichia coli and confirmation of its thymidine phosphorylase activity. Biochemistry. 31:1992;12141-12146
62. Metzger R., Danenberg K, Leichman C.G., et al. High basal level gene expression of thymidine phosphorylase (platelet derived endothelial growth factor) in colorectal tumors is associated with non-response to 5 fluorouracil. Clin. Cancer Res. 4:1998;2371-2376
63. Marchetti S., Chazal M., Dubreuil A., Fischel J.L., Etienne M.C., Milano G. Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis. Br. J. Cancer. 85:2001;439-445
64. Metzger R., Danenberg K., Leichman C.G., et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin. Cancer Res. 4(10):1998;2371-2376
65. Lu Z., Zhang R., Diasio R.B. Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J. Biol. Chem. 267:1992;17102-17109
66. Diasio R.B., Lu Z. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J. Clin. Oncol. 12:1994;2239-2242
67. Beck A., Etienne M.C., Cheradame S., et al. A role for dihydropyrimidine dehydro-genase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur. J. Cancer. 30:1994;1517-1522
68. Nita M.E., Tominaga O., Tsuruo T., Muto T. Dihydropyrimidine dehydro-genase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer. Hepato-Gastroenterology. 45:1998;2117-2122
69. Yamashita K., Mikami Y., ikeda M., et al. Gender differences in the dihydropyrimidine dehydrogenase expression and 5-fluorouracil sensitivity of colorectal cancers. Proc. Am. Soc. Clin. Oncol. 22:2003;298. [abstr 1198]
70. Salonga D., Danenberg K.D., Johnson M., et al. Colorectal tumors responding to 5-FU have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6:2000;1322-1327
71. Adlard J.W., Richman S.D., Seymour M.T., Quirke P. Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol. 3:2002;75-82
72. Berglund A., Edler D., Molin D., et al. Thymidylate synthase and p53 expression in primary tumor do not predict chemotherapy outcome in metastatic colorectal carcinoma. Anticancer Res. 22(6B):2002;3653-3659
73. Cascinu S., Catalano V., Aschele C., et al. Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination. Ann. Oncol. 11(8):2000;1053-1056
74. Elsaleh H., Powell B., Soontrapornchai P., et al. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma. Oncology. 58(1):2000;52-59
75. Leahy D.T., Mulcahy H.E., O'Donoghue D.P., Parfrey N.A. bcl-2 protein expression is associated with better prognosis in colorectal cancer. Histopathology. 4:1999;360-367
76. Manne U., Weiss H.L., Grizzle W.E. Bcl-2 expression is associated with improved prognosis in patients with distal colorectal adenocarcinomas. Int. J. Cancer. 89:2000;423-430
77. McKay J.A., Lloret C., Murray G.I., et al. Application of the enrichment approach to identify putative markers of response to 5-fluorouracil therapy in advanced colorectal carcinomas. Int. J. Oncol. 1:2000;153-158
78. Paradiso A., Simone G., Lena M.D., et al. Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer. Br. J. Cancer. 84:2001;651-658
79. Aschele C., Casazza S., Debernardis D., et al. Lack of correlation between p53 overexpression and response to Fura-based chemotherapy in advanced colorectal cancer patients. Proc. Am. Soc. Clin. Oncol. 16:1997;258a. [abstr 916]
80. Lenz H.J., Hayashi K., Salonga D., et al. p53 mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin. Cancer Res. 4:1998;1243-1250
81. Schneider H.J., Sampson S.A., Cunningham D., et al. Bcl-2 expression and response to chemotherapy in colorectal adenocarcinoma. Br. J. Cancer. 75(3):1997;427-431
82. Wright C.M., Dent O.F., Barker M., et al. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br. J. Surg. 87:2000;1197-1202
83. Gryfe R., Kim H., Hsieh E.T., et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N. Engl. J. Med. 342:2000;69-77
84. Elsaleh H., Powell B., McCaul K., et al. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin. Cancer Res. 5:2001;1343-1349
85. Gafa R., Maestri I., Matteuzzi M., et al. Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. Cancer. 89:2000;2025-2037
86. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 87:1996;159-170
87. Ribic C.M., Sargent D.J., Moore M.J., et al. Tumor microsatellite- instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349:2003;247-257
88. Entius M.M., Keller J.J., Drillenburg P., Kuypers K.C., Giardiello F.M., Offerhaus G.J. Microsatellite instability and expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome. Clin. Cancer Res. 6:2000;1784-1789
89. Van Rijnsoever M.M., Elsaleh H., McCaul K., et al. DNA methylation in stage III colorectal cancer is a novel independent predictor of survival benefit from adjuvant 5-fluorouracil treatment. Proc. Am. Soc. Clin. Oncol. 22:2003;256. [abstr 1027]
90. Steinberg S.M., Barkin J.S., Stablein D.M. Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience. Cancer. 57:1986;1866-1870
91. Kemeny N., Braun D.W. Jr. Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status and white blood cell count. Am. J. Med. 74:1983;786-794
92. Graf W., Bergstrom R., Pahlman L., Glimelius B. Appraisal of a model for prediction of prognosis in advanced colorectal cancer. Eur. J. Cancer. 30A:1994;453-457
93. Graf W., Glimelius B., Pahlman L., Bergstrom R. Determinants of prognosis in advanced colorectal cancer. Eur. J. Cancer. 27:1991;1119-1123
94. Webb A., Scott-Mackie P., Cunningham D., et al. The prognostic value of CEA, beta HCG, AFP, CA 125 CA 19-9 and C-erb B-2 immunohistochemistry in advanced colorectal cancer. Ann. Oncol. 6:1995;581-587
95. Tirion P., Cassano A., O'Dwyer P.J., et al. Meta-analysis of alpha-interferon plus 5-fluorouracil in advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. 19:2000;244a. [abstr 945]
96. Köhne C.H., Cunningham D., Di Costanzo F., et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: result of a multivariate analysis of 3825 patients. Ann. Oncol. 13:2002;308-317
97. Saltz L, Danenberg K, Paty P, et al. High TS expression does not preclude activity of CPT-11 in colorectal cancer. Proc Am Soc Clin Oncol 1998 [abstr 1080].
98. Whitacre C.M., Zborowska E., Willson J.K., Berger N.A. Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness. Clin. Cancer Res. 5:1999;665-672
99. Bras-Goncalves R.A., Rosty C., Laurent-Puig P., Soulie P., Dutrillaux B., Poupon M.F. Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status. Br. J. Cancer. 82:2000;913-922
100. Cusack J.C. Jr., Liu R., Houston M., et al. Enhanced hemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 61:2001;3340-3535
101. Freyer G., Rougier P., Bugat R., et al. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups. Br. J. Cancer. 83:2000;431-437
102. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 343:2000;905-914
103. Ishitsuka H, Miwa M, Ishikawa T, et al. Capecitabine: an orally available fluoropyrimidine with tumor selective activity. Proc Am Assoc Cancer Res 1995 [abstr 36].
104. Meropol N.J., Creaven P.J., Petrelli N.J. Metastatic colorectal cancer: advances in biochemical modulation and new drug development. Sem. Oncol. 22:1995;509-524
105. Hoff P.M., Ansari R., Batist G., et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J. Clin. Oncol. 19:2001;2282-2292
106. Park DJ, Stoehlmacher J, Zhang W, Groshen S, Lenz HJ. Human thymidylate synthase gene polymorphism determines response to capecitabine chemotherapy in advanced colorectal cancer. Proc Am Soc Clin Oncol 2001 [abstr 514].
107. Tsuji T., Hidaka S., Sawai T., et al. Polymorphism in the thymidilate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin. Canc. Res. 9(10):2003;3700-3704
108. Toi M, Tominaga T, Abe O. et al. Role of thymidine phosphorylase for predicting the prognosis and therapeutic effects of 5′-deoxy-5- fluorouridine, an intermediate form of capecitabine, in early breast cancer patients; findings from a randomized controlled trial. Proc Am Soc Clin Oncol 2001 [abstr 120].
109. Nishimura G, Ninomiya I, Fujimura T, Ohta T, Miwa K. Thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) levels in primary colorectal cancer correlated with response to doxifluridine (5′-DFUR) in adjuvant chemotherapy. Proc Am Soc Clin Oncol 2001 [abstr 598].
110. Gieschke R., Burger H.U., Reigner B., Blesch K.S., Steimer J.L. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. Br. J. Clin. Pharmacol. 55:2003;252-263
111. Bleiberg H., de Gramont A. Oxaliplatin plus 5-FU. Clinical experience in patients with advanced colorectal cancer. Sem. Oncol. 25:1998;32-39
112. Raymond E., Faivre S., Woynarowski J.M., Chaney S.G. Oxaliplatin: mechanism of action and antineoplastic activity. Sem. Oncol. 25:1998;4-12
113. Metzger R., Leichman C.G., Danenberg K.D., et al. ERCC1 MRNA levels complement TS mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and 5-fluorouracil chemotherapy. J. Clin. Oncol. 16:1998;309-316
114. Shirota Y., Stoehlmacher J., Brabender J., et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. 19:2001;4298-4304
115. Coin F., Marinoni J.F., Rodolfo C., Fribourg S., Pedrini A.M., Egly J.M. Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIIH. Nat. Genet. 20:1998;184-188
116. Shen M.R., Jones I.M., Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymophic frequency in DNA repair genes in healthy humans. Cancer Res. 58:1998;604-608
117. Spitz M.R., Wu X., Wang Y., et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res. 61:2001;1354-1357
118. Park D.J., Stoehlmacher J., Zhang W., Tsao-Wei D.D., Groshen S., Lenz H.J. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 61:2001;8654-8658
119. Bensmaine M.A., Marty M., de Gramont A., et al. Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients. Br. J. Cancer. 85:2001;509-517
120. Stoehlmacher J., Ghaderi V., Iobal S., et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res. 21(4B):2001;3075-3079
121. Van Cutsem E., Cunningham D., Maroun J., Cervantes A., Glimelius B. Raltitrexed: current clinical status and future directions. Ann. Oncol. 13:2002;513-522
122. Giacchetti S., Perpoint B., Zigani R., et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 18:2000;136-147
123. Farrugia D.C., Ford H.E., Cunningham D., et al. Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. Clin. Cancer Res. 9:2003;792-801
124. Findlay M.P., Cunningham D., Morgan C., Clinton S., Hardcastle A., Aherne G.W. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br. J. Cancer. 75:1997;903-909
125. Gorlick R., Metzger R., Danenberg K.D., et al. Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. J. Clin. Oncol. 16:1998;1465-1469
126. Patterson A., Talbot D., Stratford I., Harris A.L. Thymidine phosphorylase moderates thymidine-dependent rescue after exposure to the thymidylate synthase inhibitor ZD1694 (Tomudex) in vitro. Cancer Res. 58:1998;2737-2740
127. Shih C., Gosset L., Gates S., et al. LY231514 and its polyglutamates exhibit potent inhibition against both human dihydrofolate reductase (DHFR) and thymidylate synthase (TS): multiple folate enzyme inhibition. Ann. Oncol. 7:1996;85
128. Grindley G.B., Shih C., Barnett C.J., et al. LY231514, a novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (TS). Proc. Am. Assoc. Cancer Res. 33:1992;411
129. Broll R., Erdmann H., Duchrow M., et al. Vascular endothelial growth factor (VEGF) - a valuable serum tumour marker in patients with colorectal cancer? Eur. J. Surg. Oncol. 27:2001;37-42
130. Cascinu S., Graziano F., Valentini M., et al. Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. Ann. Oncol. 12:2001;239-244
131. Gordon M.S., Margolin K., Talpaz M., et al. Phase I safety and pharmacokinetic study of recombinant human antivascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19:2001;843-850
132. Li J.Q., Miki H., Wu F., et al. Cyclin A correlates with carcinogenesis and metastasis, and p27(kip1) correlates with lymphatic invasion, in colorectal neoplasms. Hum. Pathol. 33:20020;1006-1015
133. Ducreux M., Kohne C.H., Schwartz G.K., Vanhoefer U. Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers. Ann. Oncol. 14(Suppl. 2):2003;ii17-23
134. Sausville E.A., Johnson J., Alley M., et al. Inhibition of CDKs as a therapeutic modality. Ann. NY Acad. Sci. 910:2000;207-221
135. Esteller M., Gonzalez S., Risques R.A., et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J. Clin. Oncol. 19:2001;299-304
136. Andreyev H.J., Norman A.R., Cunningham D. Kirsten ras mutation in patients with colorectal cancer: the multicenter RASCAL study. J. Natl. Cancer Inst. 90:1998;675-684
137. Hill B.T., Perrin D., Kruczynski A. Inhibition of RAS-targeted prenylation: protein farnesyl transferase inhibitors revisited. Crit. Rev. Oncol. Hematol. 33:2000;7-23
138. Esteller M., Hamilton S.R., Burger P.C., et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59:1999;793-797
139. Scharovsky O.G., Rozados V.R., Gervasoni S.I., et al. Lynch PM. COX-2 inhibition in clinical cancer prevention. Oncology. 15:2001;21-26